Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000963 Huadong Medicine Co.,Ltd.

Closed 09-24 15:00:00

26.06

-0.44

-1.66%

High26.54	Low26.05	Vol9.25M
Open26.43	D1 Closing26.50	Amplitude1.85%
Mkt Cap45.71B	Tradable Cap45.68B	Total Shares1.75B
T/O242.00M	T/O Rate0.53%	Tradable Shares1.75B
P/B1.83	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":26.06,"timestamp":1790233386000,"preClose":26.5,"halted":0,"volume":9250529,"delay":0,"changeRate":-0.0166,"floatShares":1753000000,"shares":1754000000,"eps":1.9731,"marketStatus":"Closed","change":-0.44,"latestTime":"09-24 15:00:00","open":26.43,"high":26.54,"low":26.05,"amount":242000000,"amplitude":0.0185,"askPrice":26.07,"askSize":148,"bidPrice":26.06,"bidSize":715,"shortable":0,"etf":0,"ttmEps":1.9731,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.5,"symbolType":"stock","openAndCloseTimeList":[[1790213400000,1790220600000],[1790226000000,1790233200000]],"highLimit":29.15,"lowLimit":23.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.83,"roa":"--","peRate":13.207643,"roe":"7.31%","epsLYR":1.9484,"committee":0.693827,"marketValue":45702000000,"turnoverRate":0.0053,"status":1,"floatMarketCap":45684000000},"requestUrl":"/m/hq/s/000963/tweets","defaultTab":"tweets","newsList":[{"id":"2667016614","title":"Chinese Drug Regulator Accepts Huadong Medicine's Registration Application for Primelase Semiconductor Laser Therapy System","url":"https://stock-news.laohu8.com/highlight/detail?id=2667016614","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667016614?lang=en_us&edition=fundamental","pubTime":"2026-09-15 15:24","pubTimestamp":1789457072,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Huadong Medicine's  application for the registration of its Primelase Semiconductor Laser Therapy System, according to a Shenzhen bourse filing on Tuesday.Primelase, which is developed by subsidiary High Technology Products, is a semiconductor laser multi-parameter adjustable therapeutic device,The drugmaker's shares slipped 1% at the close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0132","BK0209","LU1969619763.USD","BK0196","BK0188","BK0175","BK0183","BK0187","000963","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662685400","title":"Heidelberg Pharma, Huadong Medicine Expand ADC Collaboration to Develop New Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2662685400","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662685400?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:48","pubTimestamp":1787906903,"startTime":"0","endTime":"0","summary":"Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidatesHeidelberg Pharma broadened its strategic partnership with Huadong Medicine via a new joint R&D collaboration","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL5n3Ls1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000963","LU1969619763.USD","BK0209","BK0188","BK0175","BK0132","BK0196","BK0187","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662720197","title":"China NMPA Clears Heidelberg Pharma’s HDP-101 Combo Trial in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662720197","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662720197?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822154,"startTime":"0","endTime":"0","summary":"China NMPA clears Heidelberg Pharma’s HDP-101 combo trial in multiple myelomaChina’s NMPA cleared a Phase Ib/II combination trial of Heidelberg Pharma’s HDP-101 in relapsed or refractory multiple myel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL20wNHl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0209","BK0183","BK0187","BK0196","LU1969619763.USD","BK0132","BK0188","LU2328871848.SGD","BK0175","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771864","title":"Huadong Medicine's H1 Profit Rises 3%, Revenue Climbs 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771864","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771864?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:04","pubTimestamp":1787817868,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  net profit attributable to shareholders in the first half rose 2.5% to 1.86 billion yuan from 1.81 billion yuan a year earlier, according to a Shenzhen bourse filing on Thursday.Earnings per share increased 2.6% year on year to 1.06 yuan from 1.03 yuan.Operating revenue climbed 1.8% to 22.1 billion yuan from 21.7 billion yuan in the previous year.The Chinese drugmaker proposed to distribute a cash dividend of 3.50 yuan per 10 shares to shareholders.The company's shares rose 1% at the close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK0196","LU2328871848.SGD","FCA","BK0132","BK0188","BK0183","BK0175","BK0187","BK0209","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662779426","title":"Huadong Medicine's Lymphoma Drug Gets US FDA's Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779426","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662779426?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:58","pubTimestamp":1787817488,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  HDM2005 for injection obtained a fast track designation from the U.S. Food and Drug Administration, according to a Shenzhen bourse filing on Thursday.The drug is being developed as a treatment for patients with relapsed or refractory mantle cell lymphoma, who had at least two lines of systemic therapy, including a BTK inhibitor.The Chinese drugmaker's shares rose 1% at the close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0132","BK0188","BK0183","LABU","BK4585","BK0209","LU1969619763.USD","LU2328871848.SGD","000963","BK0187","BK4588","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662279714","title":"Huadong Medicine H1 Net Profit up 2.53% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2662279714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662279714?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:19","pubTimestamp":1787739542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N0OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["000963","BK0209","BK0188","BK0183","BK0132","BK0196","LU1969619763.USD","BK0187","LU2328871848.SGD","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662989157","title":"Huadong Medicine Secures China Regulatory Nod For Undereye Filler","url":"https://stock-news.laohu8.com/highlight/detail?id=2662989157","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662989157?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:56","pubTimestamp":1787727365,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) UK-based aesthetic subsidiary Sinclair Pharmaceuticals has received approval from China's National Medical Products Administration for its undereye filler, MaiLiPrecise","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0183","BK0196","BK0209","BK0187","000963","BK0188","LU1969619763.USD","BK0175","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660241822","title":"Press Release: CARsgen Therapeutics Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660241822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660241822?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:15","pubTimestamp":1787098500,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results.Business Highlights-- Cash and cash equivalents were around RMB1,400 million as of June 30,2026. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,200 million. In light of operational factors, we expect to. -- During H1, 2026, CARsgen has received a total of 110 confirmed orders of. -- Satri-cel receives NMPA approval in June 2026 as world's first and only. CAR-T for solid tumors. Data of satri-cel as sequential therapy after 1L. treatment in patients with G/GEJA have been presented at the 2026 ASCO. -- Multiple allogeneic CAR T-cell products are under development based on. the proprietary THANK--u Plus platform. Among them, research results. for CT0596 in the treatment of R/R MM and PCL, as well as for CT1190B in. the treatment of R/R B--NHL, have been presented at the E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","LU0950375773.USD","LU2237443465.HKD","LU0823417653.USD","BK4560","LU1674673428.USD","BK4612","LU1046421795.USD","LU2328871848.SGD","IYZ","LU1430594728.SGD","LU2506952097.USD","LU0868494617.USD","LU2237443622.USD","SG9999001424.SGD","IE00B3PB1722.GBP","BK0187","000963","BK4534","03160","CIBR","LU0070302665.USD","IE00BVYPNV92.GBP","LU1032955483.USD","SG9999001440.SGD","TM","LU2417539215.USD","IE00B1BXHZ80.USD","BK4515","CAR","LU1929549753.HKD","LU0942090050.USD","LU2462157665.USD","BK4533","CSCO","CSCL","PC","BK0209","AIQ","BK4022","02171","LENZ","LU0203345920.USD","LU1221951129.SGD","IE00B42XCP33.USD","BK1574","CSCS","LU1599440770.SGD","BK1587","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544493","title":"CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544493","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660544493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:28","pubTimestamp":1787063306,"startTime":"0","endTime":"0","summary":"CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 millionCARsgen posted revenue of RMB 62 million, up 21.58% year over year, driven mainly by zevor-cel sales vol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbGD37X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0187","BK1587","BK1161","02171","BK0183","LU2328871848.SGD","000963","BK1574","LU1969619763.USD","BK0188","BK0196","BK1585","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658027106","title":"Huadong Medicine's UK Arm Receives EU Certification for Intradermal Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2658027106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658027106?lang=en_us&edition=fundamental","pubTime":"2026-08-10 13:04","pubTimestamp":1786338280,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  UK subsidiary, Sinclair Pharma, received European Union CE certification for its carboxymethyl chitosan injection solution, according to a Monday filing with the Shenzhen bourse.The product can be marketed in the EU, Huadong said.The product, branded Kytogen Defend, is indicated for intradermal injection, superficial filling, skin texture improvement and skin hydration, the company said. KIO015 is the product's development code.The product is the first of its kind not derived from animal products, Huadong said.Shares of the pharmaceutical company rose 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0196","BK0187","LU1969619763.USD","BK0183","BK0188","BK0209","000963","BK0132","BK4156","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145023735","title":"Huadong Medicine Subsidiary Secures EU MDR CE Certification for Medical Device","url":"https://stock-news.laohu8.com/highlight/detail?id=1145023735","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145023735?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:40","pubTimestamp":1786264814,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned UK subsidiary, Sinclair Pharma Limited (\"Sinclair\"), has obtained EU MDR CE certification for KIO015, a novel injectable...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FESXmain","BK1574","BK4585","000963","BK4109","159883","BK1100","BK4588","BK0209","BK0175","BK1583","LU1969619763.USD","IEIH","LGHT","BK0187","BK0132","HART","PSCM","RSPH","GDOC","MEDX","BK0183","LNGR","MDEV","FSXEmain","BK0196","PTH","AGNG","BK0188","LU2328871848.SGD","CE","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110023769","title":"Centralised Drug Procurement Exposes Mixed Results for Huadong Medicine, Generic Drug Division Faces Pressure Amid Transformation Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=1110023769","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110023769?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:50","pubTimestamp":1786071031,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. recently announced the preliminary results of the 12th round of national centralised drug procurement, winning bids for three products while losing bids for four core drugs....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","BK0183","BK0188","BK0175","BK0209","LU1969619763.USD","BK0196","BK0187","000963","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656340363","title":"Huadong Medicine Wins Pre-Bids for Three Drugs Under China Procurement System","url":"https://stock-news.laohu8.com/highlight/detail?id=2656340363","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656340363?lang=en_us&edition=fundamental","pubTime":"2026-08-03 12:40","pubTimestamp":1785732011,"startTime":"0","endTime":"0","summary":"Huadong Medicine  won pre-bids for three of its products under China's drug procurement program, according to a Monday disclosure to the Shanghai bourse.The pre-selected drugs include the cyclosporine soft capsules and tacrolimus capsules for immunology, as well as mesalazine enteric-coated tablets for inflammatory bowel diseases.Total sales of its winning products reached 2.08 billion yuan in 2025.Shares fell 2% during the midday break on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000963","BK0183","BK0187","LU1969619763.USD","BK0188","BK0196","BK0175","BK0209","BK0132","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120367878","title":"Huadong Medicine Chairman Proposes Interim Dividend Plan for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1120367878","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120367878?lang=en_us&edition=fundamental","pubTime":"2026-07-20 12:01","pubTimestamp":1784520082,"startTime":"0","endTime":"0","summary":"An announcement from Huadong Medicine Co.,Ltd. (SZSE: 000963) reveals a proposal by the company's Chairman, Mr. Lv Liang.The proposal, made under the authority granted by the 2025 annual general...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0188","BK0132","BK0196","BK0209","LU1969619763.USD","BK0175","BK0187","000963","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652626122","title":"Huadong Medicine's Chairman Proposes Cash Dividend Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652626122","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652626122?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:58","pubTimestamp":1784519913,"startTime":"0","endTime":"0","summary":"BRIEF-Huadong Medicine's Chairman Proposes Cash Dividend PlanJuly 20 (Reuters)-Huadong Medicine Co Ltd000963.SZ:SAYS CHAIRMAN PROPOSES CASH DIVIDEND OF 3.5 YUAN ($0.5169) (INCLUDING TAX) PER 10 SHARES TO ALL SHAREHOLDERSSource textFurther company coverage:000963.SZ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nL4N43M09C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000963","LU1969619763.USD","BK0209","BK0188","BK0175","BK0132","BK0196","BK0187","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650809945","title":"Huadong Medicine's Attributable Profit Jumps 9.6% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2650809945","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650809945?lang=en_us&edition=fundamental","pubTime":"2026-07-09 12:53","pubTimestamp":1783572811,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  attributable profit rose 9.6% to 1.00 billion yuan in the first half from 914.7 million yuan in the year-ago period, according to a Thursday filing with the Shenzhen bourse.Earnings per share at the drug maker increased 9.6% to 0.5715 yuan from 0.5213 yuan in the previous year.Operating revenue grew 4.2% year over year to 11.2 billion yuan from 10.7 billion yuan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0187","LU2328871848.SGD","BK0183","000963","FCA","LU1969619763.USD","BK0188","BK0196","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178671040","title":"Huadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1178671040","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178671040?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383921,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0175","000963","BK0196","BK0187","LU2328871848.SGD","BK0183","LU1969619763.USD","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646822927","title":"Huadong Medicine's Unit Gets Registration Certificate for V30 Skin Treatment System","url":"https://stock-news.laohu8.com/highlight/detail?id=2646822927","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646822927?lang=en_us&edition=fundamental","pubTime":"2026-06-25 14:55","pubTimestamp":1782370535,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Viora, received a medical device registration certificate from China's National Medical Products Administration for its V30 Skin Treatment System, according to a Shenzhen bourse filing on Thursday.The skin treatment platform can be used with the V-IPL IPL handpiece, V-ST RF handpiece or the V-Nd:YAG laser handpiece to reduce wrinkles, treat vascular or pigmented lesions and acne, and remove hair.The pharmaceutical company's shares fell 1% during the afternoon trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000963","BK0183","BK0187","LU1969619763.USD","BK0188","BK0196","BK0175","BK0209","BK0132","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646822959","title":"Huadong Medicine Gets China Nod for Lymphoma Combo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2646822959","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646822959?lang=en_us&edition=fundamental","pubTime":"2026-06-25 14:52","pubTimestamp":1782370369,"startTime":"0","endTime":"0","summary":"Huadong Medicine  subsidiary Zhongmei Huadong obtained the approval of China's drug regulator to conduct clinical trials of HDM2005 in combination with PD-1 and AD chemotherapy for classical Hodgkin's lymphoma.The drug is already in trials for multiple hematologic and solid tumor indications in China and the U.S., according to a Thursday filing with the Shenzhen bourse.Shares of the drugmaker declined 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0187","LU2328871848.SGD","BK0183","000963","LU1969619763.USD","BK0188","BK0196","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103413408","title":"Huadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30","url":"https://stock-news.laohu8.com/highlight/detail?id=1103413408","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103413408?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:54","pubTimestamp":1782298464,"startTime":"0","endTime":"0","summary":" Huadong Medicine Co.,Ltd. (SHE: 000963) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK0196","BK0187","LU1969619763.USD","BK0183","BK0188","BK0209","000963","BK0132","IPOS","BK0175"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790538996185,"stockEarnings":[{"period":"1week","weight":0.0101},{"period":"1month","weight":-0.0317},{"period":"3month","weight":0.0002},{"period":"6month","weight":-0.2397},{"period":"1year","weight":-0.3652},{"period":"ytd","weight":-0.3162}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":-0.0003},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100196人(较上一季度增加18.85%)","perCapita":"17495股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":"　　华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction